Despite medical innovations, maternal mortality rates in the US remain high, especially compared with those of similarly ...

Patients with acute episodic migraine consistently prioritize pain relief over other treatment attributes such as route of administration, adverse outcomes, and costs, according to study results ...

The FDA has granted marketing authorization to CT-132 for the preventive treatment of episodic migraine in patients aged 18 years and older.

Mesenchymal precursor cells plus hyaluronic acid significantly reduced chronic low back pain due to degenerative disc disease.